RecruitingNCT07643896
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
ADVANCE Study: Assay Development and Validation for Pre-Natal and Obstetric Conditions
Sponsor
BillionToOne Inc.
Enrollment
1,000 participants
Start Date
Jan 10, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
Eligibility
Sex: FEMALE
Inclusion Criteria2
- pregnant individuals between 10 and 20 weeks of gestation
- singleton gestation
Exclusion Criteria1
- \- active cancer
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07643896
Related Trials
Vascular Function in Adults With Down Syndrome
NCT076302071 location
Pregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos
NCT041098461 location
AEF0217 in Participants With Down Syndrome
NCT0733491210 locations
Oro-myofunctional Characteristics and Obstructive Sleep Apnea in Infants With Down Syndrome
NCT071952531 location
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
NCT074930961 location